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microRNA-494 and ATF3 the targets of onconase(?)
Zbigniew Darzynkiewicz
Onconase (Onc; also named ranpirnase), a 12 kD 
ribonuclease from oocytes of northern leopard frogs (Rana 
pipiens), is cytostatic and cytotoxic to variety tumor cell 
lines, inhibits growth of tumors in model animals and 
advanced to clinical trials as anticancer and antiviral drug 
[1]. Although its cytostatic and cytotoxic properties were 
recognized nearly three decades ago [2] mechanism of 
action is still elusive. The anticancer properties of Onc 
require its ribonucleolytic activity sustained by resistance 
to ribonuclease inhibitor protein that is present in cytosol 
as well as to its remarkable conformational stability. 
However, it is unclear which RNA species are preferential 
Onc targets whose destruction may explain anticancer 
specificity of this RNase. The initial observation that 
rRNA and tRNA become degraded in Onc-treated cells 
led the authors to propose that suppression of translation 
is the primary cause of its activity. However subsequent 
observations of cells sensitivity to Onc, its effect on 
the cell cycle, and complexity of other effects that lead 
to cell death were incompatible with this notion. In fact 
the evidence was accumulating that different signaling 
pathways become activated and diverse genes were up- 
and down-regulated [3]. 
In this issue of Oncotarget Vert et al., [4] report on 
their attempts to identify the Onc regulated genes that 
could explain the cytotoxic and anticancer properties of 
this RNase. Using the microarray-derived transcriptional 
profiling, confirmed by RT-qPCR, they noticed that among 
the up-regulated genes the most conspicuous is activating 
transcription factor 3 (ATF3). This was the case for both 
ovarian cancer cell lines analyzed by the authors. Together 
with up-regulation of several genes downstream of ATF3, 
the character of cell cycle changes and other effects 
leading to cell apoptosis, the data suggest that activation 
of ATF3 is the key event responsible for cytotoxicity of 
Onc and for its specificity to cancer cells. Also the prior 
studies [3] exploring the up- and down-regulation of 
different genes by Onc in malignant mesothelioma cell 
lines, conform to these findings. The reported data are also 
congruent with the observed antiviral properties of Onc 
in as much as this transcription factor can be implicated 
in suppressing viral genome replication, keeping virus 
latency or preventing viral oncogenesis [4].
The findings that ATF3 is the Onc target are in 
accordance with earlier reports that activation of ATF3 
by other than Onc means triggers signaling pathways 
that lead to apoptosis in different types of cancers. Of 
particular interest are observations that overexpression 
of ATF3 increases cell sensitivity to variety of anticancer 
drugs. Thus, there is a remarkable correspondence 
between the mentioned above effects of ATF3 and Onc 
as factors increasing sensitivity of cancer cells to other 
treatments. Namely, dozens of papers describing ability of 
Onc to sensitize cancer cells to different anticancer drugs 
are recorded in PubMed. In some of these publications 
Onc is proposed to be used as an adjunctive therapy to 
amplify effectiveness of the primary treatment. The 
suppression of NF-kB by Onc was advanced to explain its 
ability to sensitize cancer cells via decreasing resistance 
to apoptosis [5]. The involvement of NF-κB as one of the 
mechanisms by which Onc is increasing sensitivity of 
cancer cells to other drugs is consistent with up-regulation 
of ATF3 as the central event affecting transcription of the 
genome of treated cancer cells [4]. 
The noncoding RNA that provides regulation 
of genes activity via RNAi appears to be the potential 
primary target of this Onc. It was already demonstrated 
that Onc is able to attack siRNA within the cell and 
activate the siRNA-suppressed gene [6]. It is possible 
therefore that activation of ATF3 by Onc is mediated 
by targeting siRNA or other RNAi mechanisms that 
otherwise suppress activity of this gene. Thus far the 
only candidate that can be found in the literature is 
microRNA-494 which by binding to the 3′UTR of ATF3 
directly suppresses transcription of this factor. In mice its 
overexpression significantly attenuates the level of ATF3 
[7]. Perusal of the literature also shows that modulation 
of microRNA-494 has profound effects on cancer cells 
proliferation and sensitivity to apoptosis. The primary 
potential target of Onc, at present, appears to be the 
microRNA-494. 
Activation of ATF3 via RNAi by Onc does not 
preclude the eventuality that other RNA species are targets 
of Onc as well. Both rRNA and tRNA have been shown 
degraded by Onc. Our early data on human submaxillary 
carcinoma A-253 and colon adenocarcinoma Colo 320 CM 
cells indicated that in addition to reduced clonogenicity 
the size of individual cells as well of cell clones was 
substantially smaller in the Onc treated cultures [2]. 
Also the Onc treated cells had diminished RNA content. 
All this suggests that growth rate of the surviving cells 
was reduced. This may be expected if rate of translation 
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is suppressed by partial targeting rRNA and/or tRNA. 
Upon entrance of Onc into the cell, thus, equilibrium may 
develop between different rates of degradation of different 
RNA species e.g. due to differences of their accessibility 
to this RNase. As shown [4] however regardless of the 
cell type the dominant effect in terms of a loss of cell 
viability appears to be activation of transcription of ATF3. 
The data in the literature point out that ATF3 selectivity 
may provide its anticancer properties, perhaps across 
different cancer types. The antiviral properties of Onc are 
also compatible with this mechanism when different RNA 
substrates including viral genomes and host-cell nucleic 
acids used for viral replication all are accessible to Onc. 
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